Loading...

UNCY UNICYCIVE THERAPEUTICS INC Other Situations 8-K Filing

NCYC

NCY

UNICYCIVE THERAPEUTICS INC

(UNCY)

2023 8-K

Show Summary

Show Summary

Clinical Trials

Management Changes

Earnings Releases

Capital Structure Update

Financial Results

Nasdaq Compliance Notice

Financial Results

Nasdaq Compliance

Financial Results

Agreement with Shilpa Medic...

Clinical Trial Results

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Private Placement

Exchange Agreement and Cert...

Compliance Notice from Nasdaq

Earnings Reports

FDA Alignment on Oxylanthan...

Change in Accounting Firm

Earnings Reports

Resignation of Auditor

Compliance Regained

Update on New Drug Application

Annual Meeting of Stockholders

Financial Results Announcement

Amendment to Securities Pur...

Financial Results Announcement

Compliance with Nasdaq List...

Securities Purchase Agreement

Compliance Notice from Nasdaq

License Agreement with Lotu...

External Links:

Unicycive Therapeutics, Inc. entered into a License Agreement with Lotus International Pte Ltd. to develop and market Renazorb in the Republic of Korea, receiving an upfront payment of $750,000 and potential milestone payments and royalties.

AI Assistant

UNICYCIVE THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.